Modalis Therapeutics Corporation engages in the research and development of therapeutics to treat patients with serious genetic disorders. The company is developing therapies for genetic diseases using its proprietary CRISPR-GNDM an epigenome editing technology that combines dCas9. It also develops various therapeutics for muscle disorders, cardiomyopathy, and CNS disorders. The company was formerly known as EdiGENE Corporation and changed its name to Modalis Therapeutics Corporation in August 2019. Modalis Therapeutics Corporation was incorporated in 2016 and is headquartered in Chuo, Japan.
Frequently asked questions
What sector does Modalis Therapeutics Corp (4883) operate in?
Modalis Therapeutics Corp belongs to the Healthcare sector and operates in the Drug Manufacturers - Specialty & Generic industry.
What is Modalis Therapeutics Corp (4883) current stock price?
As of the latest data, Modalis Therapeutics Corp stock price is ¥33, with a previous close of ¥33.
What is Modalis Therapeutics Corp (4883) current market capitalization?
Modalis Therapeutics Corp market cap is approximately 3.44 billion.
What is Modalis Therapeutics Corp (4883) Earnings Per Share (EPS)?
The trailing EPS is -¥24.
What is Modalis Therapeutics Corp (4883) EBITDA?
Modalis Therapeutics Corp EBITDA (Earnings Before Interest, Taxes, Depreciation, and Amortization) is -657.79 million.
Does Modalis Therapeutics Corp (4883) pay dividends?
No. Modalis Therapeutics Corp does not pay a dividend.
What is Modalis Therapeutics Corp (4883) beta (volatility) score?
Modalis Therapeutics Corp has a beta of 0.404, indicating lower volatility than the overall market.
